Elusys Therapeutics, Inc. has received payment from the U.S. federal government for completing the second delivery of its medical countermeasure for inhalational anthrax, according to a Jan. 24 statement by the company. [Read more]
See what we’re reading this week at Global Biodefense on topics including improving biosurveillance systems, turning competitors into collaborators during epidemics, and therapeutic windows for ricin post-exposure treatment. BIOPREPAREDNESS Using the lessons of economics [Read more]
Emergent BioSolutions Inc. this week announced that the U.S. Department of Health and Human Services (HHS) is advancing its anthrax preparedness strategy with multiple contract actions for the company’s anthrax vaccines. On [Read more]
See what we’re reading this week at Global Biodefense on topics including CRISPR bioterror potential, accidental live anthrax use during CDP training, and global action plan for antimicrobial resistance. POLICY, PRACTICES & POLITICS Officials [Read more]
The U.S. Environmental Protection Agency has published a report focused on decontaminating railcars and related materials in the event of a biological incident in a subway system. In the event of a [Read more]
See what we’re reading this week at Global Biodefense on topics including pandemic simulations, Canada’s anthrax vaccine stockpile, animal feed biosecurity, and CRISPR’s promise for better animal models. BIOPREPAREDNESS Assessing the epidemic potential of [Read more]
An Environmental Protection Agency (EPA) study, conducted by the EPA’s Office of Research and Development National Homeland Security Research Center (NHSRC), examined methods for decontamination of drinking water infrastructure contaminated with anthrax-like [Read more]
Tetracore Inc. this week announced the successful completion of an extensive study of its Anthrax BioThreat Alert Lateral Flow Assay (LFA) and the BioThreat Alert Reader by the Department of Homeland Security [Read more]
Paratek Pharmaceuticals this week announced a new cooperative research effort with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to study omadacycline against pathogenic agents causing infectious diseases of public [Read more]
The U.S. Department of Health and Human Services has awarded a new contract to Emergent Biosolutions to support advanced development and delivery of its next-generation anthrax vaccine. The NuThrax vaccine (anthrax vaccine [Read more]
© 2018 Global Biodefense